PARP inhibitors (#PARPi) resistance is ubiquitous in the clinic. A newly discovered pan-PARP inhibitor, thioparib, is highly effective against #olaparib -resistant cancer models, which suggests that therapeutic vulnerabilities still exist in PARPi-resistant tumors.

By JY lang, ZH Miao, A Zhang, JX He & colleagues at Chinese Academy of Sciences, Shanghai, China & University of Chinese Academy of Sciences, Beijing, China

#PARPi #CancerTherapy

👉 https://doi.org/10.15252/emmm.202216235

RT @JohnEbbenMDPhD
Thanks to @quirogad & @jane_meisel for taking us through the latest in #PARPi tx in HER2- #mBC.

🔑 to ⬆️access to germline 🧬🧪 & to increasingly think in terms of patient-centered outcomes & QoL.
Inspired this holiday season by the potential to improve outcomes for patients! https://twitter.com/JohnEbbenMDPhD/status/1606104321032085511

RT @JohnEbbenMDPhD
Thanks to @quirogad & @jane_meisel for taking us through the latest in #PARPi tx in HER2- #mBC.

🔑 to ⬆️access to germline 🧬🧪 & to increasingly think in terms of patient-centered outcomes & QoL.
Inspired this holiday season by the potential to improve outcomes for patients! https://twitter.com/JohnEbbenMDPhD/status/1606104321032085511

Thanks to @quirogad & @jane_meisel for taking us through the latest in #PARPi tx in HER2- #mBC.

🔑 to ⬆️access to germline 🧬🧪 & to increasingly think in terms of patient-centered outcomes & QoL.
Inspired this holiday season by the potential to improve outcomes for patients!
---
RT @JohnEbbenMDPhD
@TumorBoardTues @jane_meisel @quirogad @MPishvaian @BreastCaupdates @BreastCancerNow @TNBCFoundation @ArielleMedford 2/5 #TumorBoardTues…
https://twitter.com/JohnEbbenMDPhD/status/1606104321032085511